This Article Full Text Full Text (PDF) All Versions of this Article: 106/2/202    most recent 01.CIR.0000021921.14653.28v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wong, G. C. Search for Related Content PubMed PubMed Citation Articles by Wong, G. C. Pubmed/NCBI databases Substance via MeSH Related Collections Coronary imaging: angiography/ultrasound/Doppler/CC Acute coronary syndromes

(Circulation. 2002;106:202.)
© 2002 American Heart Association, Inc.

Clinical Investigation and Reports

Elevations in Troponin T and I Are Associated With Abnormal Tissue Level Perfusion

A TACTICS-TIMI 18 Substudy

Graham C. Wong, MD; David A. Morrow, MD, MPH; Sabina Murphy, MPH; Nicole Kraimer, MS; Rupal Pai, BS; David James, BA; Debbie H. Robertson, RD, MS; Laura A. Demopoulos, MD; Peter DiBattiste, MD; Christopher P. Cannon, MD; C. Michael Gibson, MS, MD, for the TACTICS-TIMI 18 Study Group

From the TIMI Study Group, Boston, Mass (S.M., N.K., R.P., D.J., C.M.G.); Merck and Co, Inc, West Point, Pa (D.H.R., L.A.D., P.D.); and the Department of Medicine, Brigham and Women’s Hospital, Boston, Mass (G.C.W., D.A.M., C.P.C.).

Reprint requests to C. Michael Gibson, MS, MD, Director TIMI Data Coordinating Center, 333 Longwood Ave, Suite 402, Boston, MA 02115. E-mail mgibson{at}perfuse.org

Background— Cardiac troponin T (cTnT) and I elevations are associated with a higher risk of adverse events, a higher incidence of multivessel disease, complex lesions, and visible thrombus in the setting of non-ST elevation (NSTE) acute coronary syndromes (ACS). Other pathophysiological mechanisms underlying troponin elevation remain unclear.

Methods and Results— We evaluated the relationship between troponin elevation and tissue level perfusion using the TIMI myocardial perfusion grade (TMPG) in 310 patients with NSTE-ACS in the Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction (TACTICS-TIMI) 18 trial. TMPG 0/1 ("closed" microvasculature) was observed more frequently in cTnT-positive patients both before (58.1% versus 42.1%; P=0.007) and after percutaneous coronary intervention (55.4% versus 35.6%; P=0.004). cTnT levels were higher among patients with TMPG 0/1 versus patients with TMPG 2/3 (0.50 versus 0.31 ng/mL; P=0.006). cTnT-positive patients were more likely to have thrombus (42.5% versus 29.3%), tighter stenoses (72.0% versus 64.8%), and higher rates of TIMI flow grade 0/1 (15.6% versus 7.0%; all P<0.05). TMPG 0/1 remained independently associated with cTnT elevation (odds ratio, 1.81; P=0.02), even after adjusting for epicardial TIMI flow grade, presence of thrombus, and prior myocardial infarction. TMPG 0/1 flow both before and after intervention was associated with increased risk of death or myocardial infarction at 6 months.

Conclusions— Similar to what has been observed in the setting of ST-elevation myocardial infarction, abnormal tissue level perfusion is also associated with adverse outcomes in the NSTE-ACS setting. Independent of the presence of thrombus and abnormal flow in the epicardial artery, impaired tissue level perfusion is associated with a 1.8-fold increased risk of cTnT elevation.

Key Words: angina • perfusion • troponin • angiography • thrombosis

This article has been cited by other articles:

				F. S. Apple, S. W. Smith, L. A. Pearce, and M. M. Murakami Assessment of the Multiple-Biomarker Approach for Diagnosis of Myocardial Infarction in Patients Presenting with Symptoms Suggestive of Acute Coronary Syndrome Clin. Chem., January 1, 2009; 55(1): 93 - 100. [Abstract] [Full Text] [PDF]

				A. Jeremias, N. S. Kleiman, D. Nassif, W.-H. Hsieh, M. Pencina, K. Maresh, M. Parikh, D. E. Cutlip, R. Waksman, S. Goldberg, et al. Prevalence and Prognostic Significance of Preprocedural Cardiac Troponin Elevation Among Patients With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: Results From the Evaluation of Drug Eluting Stents and Ischemic Events Registry Circulation, August 5, 2008; 118(6): 632 - 638. [Abstract] [Full Text] [PDF]

				F. S. Apple, S. W. Smith, L. A. Pearce, R. Ler, and M. M. Murakami Use of the Centaur TnI-Ultra Assay for Detection of Myocardial Infarction and Adverse Events in Patients Presenting With Symptoms Suggestive of Acute Coronary Syndrome Clin. Chem., April 1, 2008; 54(4): 723 - 728. [Abstract] [Full Text] [PDF]

				NACB WRITING GROUP MEMBERS, D. A. Morrow, C. P. Cannon, R. L. Jesse, L. K. Newby, J. Ravkilde, A. B. Storrow, A. H.B. Wu, and R. H. Christenson National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes Circulation, April 3, 2007; 115(13): e356 - e375. [Full Text] [PDF]

				NACB WRITING GROUP MEMBERS, D. A. Morrow, C. P. Cannon, R. L. Jesse, L. K. Newby, J. Ravkilde, A. B. Storrow, A. H.B. Wu, R. H. Christenson, NACB COMMITTEE MEMBERS, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes Clin. Chem., April 1, 2007; 53(4): 552 - 574. [Full Text] [PDF]

				A. J. Kirtane, J. J. Vafai, S. A. Murphy, J. M. Aroesty, M. S. Sabatine, C. P. Cannon, C. M. Gibson, and for the TIMI Study Group Angiographically evident thrombus following fibrinolytic therapy is associated with impaired myocardial perfusion in STEMI: a CLARITY-TIMI 28 substudy Eur. Heart J., September 1, 2006; 27(17): 2040 - 2045. [Abstract] [Full Text] [PDF]

				A. S. Jaffe, L. Babuin, and F. S. Apple Biomarkers in Acute Cardiac Disease: The Present and the Future J. Am. Coll. Cardiol., July 4, 2006; 48(1): 1 - 11. [Abstract] [Full Text] [PDF]

				W. L. Miller, K. N. Garratt, M. F. Burritt, R. J. Lennon, G. S. Reeder, and A. S. Jaffe Baseline troponin level: key to understanding the importance of post-PCI troponin elevations Eur. Heart J., May 1, 2006; 27(9): 1061 - 1069. [Abstract] [Full Text] [PDF]

				L. Babuin and A. S. Jaffe Troponin: the biomarker of choice for the detection of cardiac injury Can. Med. Assoc. J., November 8, 2005; 173(10): 1191 - 1202. [Abstract] [Full Text] [PDF]

				L. Bolognese, G. Falsini, F. Liistro, and P. Angioli Myocardial damage during percutaneous interventions for non-ST-elevation acute coronary syndromes Eur. Heart J. Suppl., October 1, 2005; 7(suppl_K): K15 - K18. [Abstract] [Full Text] [PDF]

				M. T. Roe, E. D. Peterson, Y. Li, C. V. Pollack Jr, R. H. Christenson, W. F. Peacock, F. M. Fesmire, L. K. Newby, R. L. Jesse, J. W. Hoekstra, et al. Relationship Between Risk Stratification by Cardiac Troponin Level and Adherence to Guidelines for Non-ST-Segment Elevation Acute Coronary Syndromes Arch Intern Med, September 12, 2005; 165(16): 1870 - 1876. [Abstract] [Full Text] [PDF]

				A. Jeremias and C. M. Gibson Narrative Review: Alternative Causes for Elevated Cardiac Troponin Levels when Acute Coronary Syndromes Are Excluded Ann Intern Med, May 3, 2005; 142(9): 786 - 791. [Abstract] [Full Text] [PDF]

				H. Dokainish, M. Pillai, S. A. Murphy, P. M. DiBattiste, M. J. Schweiger, A. Lotfi, D. A. Morrow, C. P. Cannon, E. Braunwald, N. Lakkis, et al. Prognostic implications of elevated troponin in patients with suspected acute coronary syndrome but no critical epicardial coronary disease: A TACTICS-TIMI-18 substudy J. Am. Coll. Cardiol., January 4, 2005; 45(1): 19 - 24. [Abstract] [Full Text] [PDF]

				R. F. Salamonsen, H.-G. Schneider, M. Bailey, and A. J. Taylor Cardiac Troponin I Concentrations, but Not Electrocardiographic Results, Predict an Extended Hospital Stay after Coronary Artery Bypass Graft Surgery Clin. Chem., January 1, 2005; 51(1): 40 - 46. [Abstract] [Full Text] [PDF]

				L. Bolognese, K. Ducci, P. Angioli, G. Falsini, F. Liistro, S. Baldassarre, and A. Burali Elevations in Troponin I After Percutaneous Coronary Interventions Are Associated With Abnormal Tissue-Level Perfusion in High-Risk Patients With Non-ST-Segment-Elevation Acute Coronary Syndromes Circulation, September 21, 2004; 110(12): 1592 - 1597. [Abstract] [Full Text] [PDF]

				C. M. Gibson and A. Schomig Coronary and Myocardial Angiography: Angiographic Assessment of Both Epicardial and Myocardial Perfusion Circulation, June 29, 2004; 109(25): 3096 - 3105. [Full Text] [PDF]

				S. Baldus, C. Heeschen, T. Meinertz, A. M. Zeiher, J. P. Eiserich, T. Munzel, M. L. Simoons, C. W. Hamm, and on behalf of the CAPTURE Investigators Myeloperoxidase Serum Levels Predict Risk in Patients With Acute Coronary Syndromes Circulation, September 23, 2003; 108(12): 1440 - 1445. [Abstract] [Full Text] [PDF]

				J. Schulz-Menger, M. Gross, D. Messroghli, F. Uhlich, R. Dietz, and M. G. Friedrich Cardiovascular magnetic resonance ofacute myocardial infarction at a very early stage J. Am. Coll. Cardiol., August 6, 2003; 42(3): 513 - 518. [Abstract] [Full Text] [PDF]

				C. M. Gibson Has My Patient Achieved Adequate Myocardial Reperfusion? Circulation, August 5, 2003; 108(5): 504 - 507. [Full Text] [PDF]

				D. A. Morrow and E. Braunwald Future of Biomarkers in Acute Coronary Syndromes: Moving Toward a Multimarker Strategy Circulation, July 22, 2003; 108(3): 250 - 252. [Full Text] [PDF]

				J. P.S. Henriques, F. Zijlstra, A. W.J. van 't Hof, M.-J. de Boer, J.-H. E. Dambrink, M. Gosselink, J. C.A. Hoorntje, and H. Suryapranata Angiographic Assessment of Reperfusion in Acute Myocardial Infarction by Myocardial Blush Grade Circulation, April 29, 2003; 107(16): 2115 - 2119. [Abstract] [Full Text] [PDF]

				C. P. Cannon Small molecule glycoprotein IIb/IIIa receptor inhibitors as upstream therapy in acute coronary syndromes: Insights from the TACTICS TIMI-18 trial J. Am. Coll. Cardiol., February 19, 2003; 41(4_Suppl_S): 43S - 48S. [Abstract] [Full Text] [PDF]